Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability

被引:33
作者
Evoy, Kirk E. [1 ,2 ]
Peckham, Alyssa M. [3 ,4 ]
Covvey, Jordan R. [5 ]
Tidgewell, Kevin J. [5 ]
机构
[1] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA
[2] Univ Hlth Syst, San Antonio, TX USA
[3] Northeastern Univ, Sch Pharm, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Dept Pharm, Boston, MA 02114 USA
[5] Duquesne Univ, Sch Pharm, Pittsburgh, PA 15219 USA
关键词
abuse; gabapentin; gabapentinoids; misuse; pharmacology; pregabalin; SYRINGE SERVICES PROGRAM; PREGABALIN PRESCRIPTIONS; RISK BEHAVIORS; ABUSE; DRUG; WITHDRAWAL; OVERDOSE; TRENDS; DEPENDENCE; DIVERSION;
D O I
10.1002/jcph.1833
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article will review the epidemiology and pharmacology of gabapentinoids (gabapentin and pregabalin) relevant to their emerging misuse potential and provide guidance for clinical and regulatory management. Gabapentinoids are gamma-aminobutyric acid analogues that produce their therapeutic effects by inhibiting voltage-gated calcium channels and decreasing neurotransmitter release. Recently gabapentinoid prescribing and use have increased tremendously. Although traditionally thought to possess a favorable safety profile, gabapentinoid misuse has also risen significantly. Gabapentinoid misuse generally occurs in combination with other substances, most notably opioids, and may be for purposes of eliciting euphoric effects, enhancing the effects of other substances, or self-treating conditions such as withdrawal, pain, anxiety, or insomnia. Given its faster onset, increased bioavailability and potency, and nonsaturable absorption, pregabalin's pharmacokinetics theoretically enhance its misuse liability versus gabapentin. However, gabapentin can produce similar euphoric effects, and epidemiologic studies have identified higher rates of gabapentin misuse in the United States, likely because of greater availability and less regulated prescribing. Although adverse events of gabapentinoid-only ingestion are relatively benign, a growing body of evidence indicates that gabapentinoids significantly increase opioid-related morbidity and mortality when used concomitantly. In addition, significant withdrawal effects may occur on abrupt discontinuation. As a result of these trends, several US states have begun to further regulate gabapentinoid prescribing, reclassifying it as a controlled substance or mandating reporting to local prescription drug-monitoring programs. Although increased regulation of gabapentin prescribing may be warranted, harm reduction efforts and increased patient and provider education are necessary to mitigate this concerning gabapentinoid misuse trend.
引用
收藏
页码:S89 / S99
页数:11
相关论文
共 96 条
[51]   Withdrawal symptoms after gabapentin discontinuation [J].
Hellwig, Thaddaus R. ;
Hammerquist, Rhonda ;
Termaat, Jill .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (11) :910-912
[52]   Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study [J].
Huybrechts, Krista F. ;
Bateman, Brian T. ;
Desai, Rishi J. ;
Hernandez-Diaz, Sonia ;
Rough, Kathryn ;
Mogun, Helen ;
Kerzner, Leslie S. ;
Davis, Jonathan M. ;
Stover, Megan ;
Bartels, Devan ;
Cottral, Jennifer ;
Patorno, Elisabetta .
BMJ-BRITISH MEDICAL JOURNAL, 2017, 358
[53]  
IQVIA Institute for Human Data Science, MED US SPEND US REV
[54]   Gabapentinoid Use in the United States 2002 Through 2015 [J].
Johansen, Michael E. .
JAMA INTERNAL MEDICINE, 2018, 178 (02) :292-294
[55]   Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK [J].
Kapil, Vikas ;
Green, Jody L. ;
Le Lait, Marie-Claire ;
Wood, David M. ;
Dargan, Paul I. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (01) :190-191
[56]  
Karavolis ZA., STATE LEVEL RESPONSE
[57]   The diversion of nonscheduled psychoactive prescription medications in the United States, 2002 to 2017 [J].
Kurtz, Steven P. ;
Buttram, Mance E. ;
Margolin, Zachary R. ;
Wogenstahl, Kevin .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (05) :700-706
[58]   Loperamide Trends in Abuse and Misuse Over 13 Years: 2002-2015 [J].
Lasoff, Daniel R. ;
Koh, Cynthia H. ;
Corbett, Bryan ;
Minns, Alicia B. ;
Cantrell, F. Lee .
PHARMACOTHERAPY, 2017, 37 (02) :249-253
[59]   An Atypical Withdrawal Syndrome in Neonates Prenatally Exposed to Gabapentin and Opioids [J].
Loudin, Sean ;
Murray, Sara ;
Prunty, Leesa ;
Davies, Todd ;
Evans, Joseph ;
Werthammer, Joseph .
JOURNAL OF PEDIATRICS, 2017, 181 :286-288
[60]   Risk to heroin users of polydrug use of pregabalin or gabapentin [J].
Lyndon, Abigail ;
Audrey, Suzanne ;
Wells, Claudia ;
Burnell, Erica S. ;
Ingle, Suzanne ;
Hill, Rob ;
Hickman, Matthew ;
Henderson, Graeme .
ADDICTION, 2017, 112 (09) :1580-1589